Laboratory leaders worldwide are embracing digital pathology and artificial intelligence as essential tools to address mounting staffing shortages and financial pressures whilst advancing precision medicine initiatives. A comprehensive survey of 360 senior professionals reveals overwhelming confidence in AI-driven pathology’s readiness for clinical implementation.
Sartorius Stedim Biotech has secured exclusive global distribution rights for NanoSpark® immune cell activation reagents, investing up to US$3 million in Nanotein Technologies whilst establishing a joint development programme targeting enhanced T cell and NK cell manufacturing workflows for cellular therapy applications.
Biological reagent supplier Antibodies.com has made a strategic relocation to Cambridge Technopark, which reflects sustained global growth, with its customer base tripling over five years to serve over 5,000 research institutions worldwide across more than 100 countries.
Danish pharmaceutical giant Novo Nordisk has appointed Maziar Mike Doustdar as chief executive officer, bringing his proven track record of doubling international sales over the past decade. The leadership transition coincides with strategic R&D consolidation as the company positions itself to address rapidly developing diabetes and obesity markets.
Enhanced Genomics has partnered with Cambridge University’s ALBORADA Drug Discovery Institute to identify novel therapeutic targets for Alzheimer’s disease using advanced 3D multi-omics technology. The collaboration has already yielded multiple previously undetectable targets, potentially accelerating drug discovery timelines across neurodegenerative diseases.
Logical Biological has established Logical Antigen, a specialist sister company focused on rapid customisation of high-quality antigens and biological materials. The new venture addresses critical supply chain challenges in the IVD market, offering streamlined protein purification services that reduce traditional development timelines from years to weeks through innovative extraction and engineering techniques.
Global nonprofit DEBRA Research has established a preclinical research collaboration with Queen Mary University of London to enhance drug development capabilities for epidermolysis bullosa, addressing critical bottlenecks in therapeutic advancement for this rare genetic skin disorder through innovative academic-philanthropic partnership models.
Cambridge-based 4basebio has launched refreshed branding and a new website following its £40 million investment round, as the AIM-listed company positions itself for growth in synthetic DNA manufacturing for next-generation therapeutics including gene therapy, RNA therapeutics and vaccine development.
Cherwell Laboratories, the established cleanroom microbiology specialist will transition to AnalytiChem UK from September 2025, marking the completion of its integration with the global AnalytiChem Group whilst maintaining its 54-year heritage in pharmaceutical manufacturing support and quality control solutions.
Clinical-stage radiopharmaceutical company ARTBIO has completed a substantial $132 million Series B financing round to advance its pipeline of alpha radioligand therapies, expand manufacturing capabilities, and support Phase II development of lead candidate AB001 for metastatic castration-resistant prostate cancer.
November 2025
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.